Furthermore, we demonstrated that semaglutide, a GLP-1RA marketed as Ozempic, promotes tumor cell growth in vitro and in vivo in human small bowel and pancreatic NET GLP-1R-expressing cell lines by activating the mitogen-activated protein kinase (MAPK) pathway (Fig. 1A), but not in those that lack the receptor (11). This evidence concerns the gene GLP1R and neoplasm.